SEC Form 4 · accession 0001493152-18-000671
ONCOSEC MEDICAL Inc · ONCS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel J. O'Connor
Officer — CEO · Director
Period of report
Sep 1, 2017
Accepted (ET)
Jan 17, 2018 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444307
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F3,F1,F4 | $1.25 | Jan 12, 2018 | A | 2,000,000 | A | Jan 12, 2018 | Nov 7, 2027 | Common Stock | 2,000,000 | 2,000,000 | D |
| Stock Option (Right to Buy)F2,F3,F1,F5 | $1.25 | Jan 12, 2018 | A | 500,000 | A | Jan 12, 2018 | Nov 7, 2027 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1OncoSec's (ONCS) stock closing price was $1.25 on November 7, 2017.
- F2The above listed Stock Options were approved by OncoSec's stockholders at OncoSec's Annual Stockholders Meeting held on January 12, 2018.
- F3The shares subject to the stock option were approved by the Company's Board of Directors on November 7, 2017 ("Grant Date"), contingent upon approval by the Company's stockholders at the Company's Annual Stockholders Meeting on January 12, 2018.
- F4One million (1,000,000) Options vested upon the Company's stockholders' approval of the Option at the Company's Annual Stockholders Meeting held on January 12, 2018 and one twenty-fourth (1/24th) of the remaining one million (1,000,000) Options shall vest on each monthly anniversary of the date of the Grant Date.
- F5The stock option were approved by the Company's Board of Directors on November 7, 2017 ("Grant Date"), subject to stockholder approval and the Company's stockholders approved the grant at the Company's Annual Stockholders Meeting on January 12, 2018. Subject to the terms of the Company's 2011 Stock Incentive Plan and related award agreement, two hundred fifty thousand (250,000) of the options shall be fully vested on the date that the Company achieves one hundred percent (100%) enrollment in the first cohort of the Pisces Study (the "Enrollment Date") and the remaining two hundred fifty thousand (250,000) PISCES Options shall vest on the first anniversary of the Enrollment Date, pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan.